148 related articles for article (PubMed ID: 35398936)
1. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
Demarez B; Eté M; David L; Quiles N; Archier E
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
[No Abstract] [Full Text] [Related]
2. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
Carrabba NV; Siliezar PD; Laylani N; Lee AG
Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
[No Abstract] [Full Text] [Related]
3. What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?
Rutkowski P; Rogala P
Expert Opin Pharmacother; 2023; 24(10):1101-1103. PubMed ID: 37144819
[No Abstract] [Full Text] [Related]
4. [Subretinal fluid associated with MEK and BRAF inhibitors].
Attia R; Comet A; Stolowy N; Fitoussi R; Michel T; Denis D; David T
J Fr Ophtalmol; 2022 Nov; 45(9):1091-1092. PubMed ID: 35908992
[No Abstract] [Full Text] [Related]
5. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment.
Obaru C; Kimura T; Yamamura M; Kuriyama H; Kashiwada-Nakamura K; Mizuhashi S; Matsumura T; Watanabe T; Inoue T; Fukushima S
J Dermatol; 2024 Apr; 51(4):e115-e117. PubMed ID: 37927219
[No Abstract] [Full Text] [Related]
6. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.
Marani A; Gioacchini H; Paolinelli M; Offidani A; Campanati A
Expert Opin Drug Metab Toxicol; 2023; 19(8):555-567. PubMed ID: 37659065
[TBL] [Abstract][Full Text] [Related]
7. Panniculitis in patients treated with BRAF/MEK inhibitors: Presentation of 4 new cases.
Cordeiro González P; Taibo Martínez A; Peña Penabad C
Med Clin (Barc); 2022 Jun; 158(11):e8-e9. PubMed ID: 34996624
[No Abstract] [Full Text] [Related]
8. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
[TBL] [Abstract][Full Text] [Related]
9. Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.
Bormann JL; Kerkvliet AM
Cutis; 2023 Sep; 112(3):E17-E20. PubMed ID: 37903392
[No Abstract] [Full Text] [Related]
10. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.
Kim DY; Swetter SM; Huhmann L; Dizon MP; Ferguson JM; Osborne TF; Spence AC; Ziad A; Fillmore N; Hartman RI
J Am Acad Dermatol; 2024 Mar; 90(3):620-623. PubMed ID: 37924953
[No Abstract] [Full Text] [Related]
12. Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
Buchacher L; Richtig G; Dernoscheg M; Richtig E; Koch L
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e605-e607. PubMed ID: 36645848
[No Abstract] [Full Text] [Related]
13. [Treatment combinations in BRAF-mutant metastatic melanoma.].
Depenni R
Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
[TBL] [Abstract][Full Text] [Related]
16. BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval.
Mullard A
Nat Rev Drug Discov; 2022 Aug; 21(8):548. PubMed ID: 35794466
[No Abstract] [Full Text] [Related]
17. Tumor lysis syndrome induced by BRAF/MEK double blockade in a patient with metastatic melanoma: A first case report.
Tachibana K; Ohe S; Tanaka M; Maniwa T; Isei T
J Dermatol; 2021 Jul; 48(7):e324-e326. PubMed ID: 33990995
[No Abstract] [Full Text] [Related]
18. [Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].
Leenhardt F; Mbatchi L; Evrard A; Cupissol D; Lesage C
Bull Cancer; 2023; 110(7-8):865-868. PubMed ID: 36966054
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
20. Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
Le Goubey JB; Sassier M; Nakouri I; De Pontville M; Césaire L; Aide N; Kottler D
Melanoma Res; 2023 Apr; 33(2):159-161. PubMed ID: 36815470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
